Kornimate/medical-research-clean huggingface dataset:
weight changes after incretin-mimetics

Conditions: Obesity and Obesity-related Medical Conditions

Summary: the goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. the main question the investigators aim to answer is: can weight regain be predicted by measuring circulating agouti-related peptide, a small protein coming from the brain?

this study will enroll people who are taking an injectable weight loss drug, have lost weight with the help of this drug, and are required by their health insurance plan to discontinue treatment. participants will first be screened for health conditions that would prevent them from entering the study. once enrolled, participants will be asked to have the following testing while still on the injectable weight loss drug: body weight measurement, body composition (fat and lean mass), resting energy expenditure (calories burned), multiple blood draws after overnight fast and after drinking and nutritional shake urine collection, urine collection, measurement of heart rate, measurement of physical activity and sleep, questionnaires. participants will then stop taking the injectable weight loss drug when the prescription runs out, and the same tests will be repeated 3 months later.

Eligibility criteria:
inclusion criteria: * adults 18 years or older * men and women * prescribed an incretin-mimetic for weight loss and for whom insurance coverage for this specific drug will lapse * any ethnicity exclusion criteria: * weight \> or = 400 lb * type 1 or type 2 diabetes * patients taking steroid medications * anemia * heart disease * advanced kidney disease (ckd stage 4 and 5) * decompensated liver disease * hyperthyroidism * untreated hypothyroidism * active cancer * post solid organ or bone marrow transplant * hiv/aids * pregnancy/plan for pregnancy in the next 6 months * breastfeeding * post-menopausal women * current smoker * current recreational drug use * night shift or rotating shift workers

Keywords: obesity weight loss weight gain
parallel study between bmp-2 and autologous bone graft after ilizarow treatment

Conditions: Bone Degenerative Changes; Osteoarthritis; Degenerative Disorder of Bone

Summary: results of growth factors indicate that bone morphogenetic proteins (bmp) have an exceptional ability to stimulate different characteristics of mesenchymale cells to osseous cells. local application of bmp results in an increase of osseous tissue regardless of the location of the growth factor. 5 years clinical studies show that bmp's can stimulate an increase of osseous tissue and improve clinical results when autologous bone graft is reduced or removed. the purpose of this study is to examine whether recombinant growth factor bmp-2 can replace autologous bone graft in order to stimulating ossification during transplantation of osseous tissue.


Eligibility criteria:
inclusion criteria: * hospitalised for autologous bone graft based on ilizarow treatment. * age between 20 and 70 years. exclusion criteria: * rheumatoid osteoarthritis * malignant disease * current hormone treatment (glucocorticoid, parathyreoidea, thyreoidea) * pregnancy * abuse of drugs and alcohol * need of long-term nsaid treatment * breastfeeding women

Keywords: bone morphogenetic protein ilizarow autologous osteoarthritis
minimal access surgical technique (mast) in obese patients in degenerative lumbar disease. a prospective long-term evaluation

Conditions: Degenerative Lumbar Disease

Summary: being confronted more and more with obese as well as older patients, minimally invasive surgery is said to keep the surgical trauma low. the prospective long-term evaluation is the continuous monitoring of patients undergoing lumbar minimally invasive fusion surgery and analyzing the effect of body mass index (bmi) and wound healing.


Eligibility criteria:
* all patients who will undergo minimally access surgical technique for degenerative lumbar disease fusion surger * patient willing to participate in observational study and who signs patient information and patient consent form * patient older that 18 years * all products will be used within intended use
assessing the effects of omega-3 supplementation on serum hsp27, hsp70, ykl40, bmp-4 levels in male patient with cad

Conditions: Cardiovascular Disease

Summary: the aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of bmp-4, ykl40, hsp70, hsp27 in patients with cardiovascular disease.

the aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of bmp-4, ykl40, hsp70, hsp27 in patients with cardiovascular disease. in this randomized, double-blind clinical trial, placebo-controlled, single-center, and phase two trials, 42men aged 45-65 years with coronary artery disease are enrolled in the study from tehran heart center. after signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days will be taken from the participants at the beginning and the end of the study,. selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. the supplement group, will receive 4 g/day omega 3 fatty acid for 8 weeks and the placebo group will also receive placebo (containing 4 g of edible paraffin) (similar in terms of color, shape and size). patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. blood samples will be collected after 8-12 hours fasting and anthropometric variables, biochemical parameters and physical activity before and after the trial will be measured.

Eligibility criteria:
inclusion criteria: * cvd patients 45- 65 years old, patients with ≥ 50% stenosis in at least one coronary angiogram demonstrated, body mass index in the range 18.5- 35, avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention, willingness to participation, exclusion criteria: * people who have used omega 3 supplements in last 3 months, having chronic renal disease , gi disease, hepatobiliary diseases, hematological disorders, hypo- or hyperthyroidism, smokers

Keywords: atherosclerotic bmp-4 ykl40 hsp70 hsp27
a combination treatment reduces acne severity and pihp

Conditions: Acne; Postinflammatory Hyperpigmentation

Summary: acne is a chronic, inflammatory skin condition. it may cause scars and post-inflammatory hyperpigmentation (pihp). pihp frequently affects individuals with a phototype of iv or above.\[1\] pihp is worsened by uv radiation, lasts for years and impacts the individual well-being.\[2, 3\] in an observational study, 1785 adults with a phototype ranging from iv to vi with acne and pihp applied daily for 2 months a dermocosmetic and a tainted sunscreen product (dc, effaclar® duo (+); ss, anthelios® shaka fluide spf 50+, ss; both la roche-posay laboratoire dermatologique, france.


Eligibility criteria:
inclusion criteria: * adult * mild to moderate acne * presence of postinflammatory hyperpigmentation lesions * phototype iv to vi exclusion criteria: * less than 18 years * severe acne
changes in sensory block level during a programmed intermittent epidural bolus regimen for labor analgesia: an observational cohort study

Conditions: Labor Pain

Summary: epidural analgesia is widely used for managing pain during labor. the programmed intermittent epidural bolus (pieb) technique has been shown to produce less consumption of local anesthetics, better sensory block, less motor block, and increased maternal satisfaction than other epidural analgesia techniques. despite all benefits from pieb, such practice has been associated with high sensory block levels. therefore, assessment of the sensory block level is an essential component of clinical safety. the lack of a standardized technique and timing to assess the sensory block level can lead to inappropriate management. the purpose of this study is to investigate the changes in block level over time, during cycles of a pieb regimen. the investigators hypothesize that these levels will be highest soon after the pieb bolus and lowest preceding the subsequent pieb bolus. the investigators also want to investigate a possible correlation between these changes in sensory block levels and motor block, pain scores, and rescue bolus of local anesthetics.


Eligibility criteria:
inclusion criteria: * women admitted to the labor and delivery unit at mount sinai hospital that request and have no contraindications to receive epidural analgesia * 18 years old or more * capable of understanding and signing the written informed consent * have no language barrier to respond to the level of sensory block assessment * and have no conditions that could compromise the body sensitivity to cold. exclusion criteria: * unintentional dural puncture during labour epidural placement * do not achieve adequate pain control 20 minutes after the loading dose (numeric rating scale (nrs)\>1 on a 0-10 nrs), * deliver before 160 minutes following the loading dose * require rescue boluses in the first 80 minutes after initiation of pieb (that is, before the 2nd pieb bolus) * withdraw their consent.

Keywords: programmed intermittent epidural bolus epidural analgesia labor epidural sensory block
live and interactive fitness training program (vivo knee oa)

Conditions: Knee Osteoarthritis

Summary: potential participants will be screened at clinic. patients who meet eligibility criteria will be considered for study. after written informed consent is obtained, participants will complete baseline testing and participants who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: vivo arm: vivo twice a week for 6 months and usual care arm: meet with atc and given medbridge home exercise program for 6 months. all participants will be followed for 12 months, and will be assessed at 3-,6-, and 12-months. all participants will complete functional assessments, oa patient reported outcomes measures, quality of life, exercise self-efficacy, and fall risk questionnaires, and health care utilization report at each testing visit. a subset of vivo participants will be asked satisfaction questions at the 3 and 6 month time points.


Eligibility criteria:
inclusion criteria: * 55-85 years of age * diagnosis of osteoarthritis within the prior 6 months * symptomatic oa defined as self-report: * pain in the knee(s) on most days of the month * difficulty with at least one of the following because of knee pain: * walking ¼ of a mile * climbing stairs * getting in and out of a car, bath, or bed * rising from a chair * or performing shopping, cleaning, or self-care activities * radiographic kl grade ii-iii (using kellgren and lawrence criteria) of one or both knees * physically able to participate in strength training - able to do one chair stand unassisted in order to test change in 30-second chair stand * ambulatory and community-dwelling * sedentary or insufficiently active as measured by the pavs * access to wi-fi in defined exercise space * bmi of 20-34.9 kg/m2 * document medication specific to oa and knee pain * willing and able to provide consent exclusion criteria: * neurological conditions causing functional impairments (parkinson's disease, ms, als) * diagnosis of dementia * inability to complete ≥1 adls without assistance. * knee surgery in the past 6 months * severe osteoporosis t-score \< -3.5 * no concurrent enrollment in physical therapy for knee pain * no concurrent enrollment in the intermountain arthrofit program * under the age of 55 or ≥85 * asymptomatic oa * not having knee pain or having significant knee pain (womac pain score of ≤3 or ≥18) * kl grade 1 or 4 * bmi above 34.9 kg/m2 or ≤20 kg/m2 * participation in formal strength training more than 30 minutes a week in the past 6 months. * pavs - participating in 150 minutes per week of moderate intensity physical activity or 75 minutes of vigorous intensity activity, or an equivalent combination of moderate and vigorous intensity physical activity. * co-morbid disease that would threaten safety or impair ability to participate in a live and interactive strength training program * symptomatic or severe coronary artery disease; peripheral vascular disease * untreated hypertension * active cancer other than skin cancer
serial collection of primary progressive multiple sclerosis participants in the murdock study

Conditions: Primary Progressive Multiple Sclerosis

Summary: the goal of this study is to enroll 100 participants with primary progressive multiple sclerosis (ppms) that have joined the murdock study horizon 1.5 (duke irb pro00011196) and the multiple sclerosis cohort (duke irb pro00023791). all 100 participants will complete a biannual collection of a follow up questionnaire and blood/urine collection for a period of 5 years.

unlike relapsing remitting multiple sclerosis (rrms) or secondary progressive multiple sclerosis (spms) in which patients experience a remission or lessening of their symptoms, primary progressive multiple sclerosis (ppms) is characterized by progression of disability from onset, with no, or only occasional and minor, remissions and improvements. the age of onset for the primary progressive subtype is later than for the relapsing-remitting, but similar to mean the age of progression between the relapsing-remitting and the secondary progressive - around 40 years of age. because of its prevalence, rrms represents the largest basis for basic and clinical ms research. therefore, drugs have primarily been developed to slow disease progression in rrms and spms patients. no treatment has been proven successful in treating primary progressive ms. the murdock-ms collection represents a unique opportunity to carry out detailed biomarker research on ppms patients and, to the knowledge of this investigator and his colleagues in the field, would represent an exceptional cohort that is not available elsewhere in the us or the rest of the world. aside from first in disease sampling, the serial, biannual collection of samples from ppms patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from rrms patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression. this progressive etiology would provide valuable insight into ppms development and may also shed light on spms progression.

Eligibility criteria:
inclusion criteria: * enrolled in the murdock study horizon 1.5 (pro00011196) * enrolled in the multiple sclerosis cohort (pro00023791) * diagnosed with primary progressive multiple sclerosis * at least 18 years of age exclusion criteria: * participants not willing to participate or sign informed consent

Keywords: primary progressive multiple sclerosis multiple sclerosis biomarker 'omic progression
burnout and approach to bereavement initiatives in a medical intensive care unit (icu)

Conditions: Burnout, Professional

Summary: given the stress, exhaustion and close interface with death that intensive care unit (icu) health care providers face, this study will evaluate burnout rates in intensive care unit (icu) physicians, nurses and ancillary staff. investigators will also study the effect on a bereavement card on these burnout rates

this study will evaluate: 1. burnout rates among nurses and ancillary staff with the abbreviated maslach burnout inventory. this is a well validated tool that is used to evaluate symptoms of burnout such as denationalization, emotional exhaustion and lack of personal accomplishment. 2. burnout rates at the beginning of and at the end of the house staff's icu rotation to gauge the effect of an icu rotation on burnout rates amon medical trainees. 3. determine whether the introduction of a bereavement card will improve symptoms of burnout as gauged by the abbreviated maslach burnout inventory 4. staff perceptions and response to the introduction of a bereavement

Eligibility criteria:
inclusion criteria: * health care providers who work in the bellevue hospital medical icu exclusion criteria: * na
home-based resistance training to patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to compare motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise (elastic band to non-elastic band) to improve physical activity, muscle strength, body composition, and self-efficacy of exercise in type 2 diabetic patients. the effectiveness of performance and exercise compliance.

this study adopts an experimental research design. a total of 90 cases of type 2 diabetes who are not exercising regularly are recruited from the outpatient clinic of the metabolism department of a medical center in the north to participate in the study. blocks 6, and 12 (block) are randomly assigned. the research subjects were assigned to the behavior change and resistance exercise group, and home-based resistance exercise( with elastic band), and the control group. the behavior changes and resistance exercise group received motivational interviews and self-efficacy theory-based exercise behavior changes and resistance exercise guidance intervention, home resistance exercise. the group received home elastic band resistance exercise training, and the control group received regular exercise guidance. the three groups received data collection of physical activity, muscle strength, body composition, physical activity function, and exercise self-efficacy in the pre-test, the sixth week, and the twelfth week. during the study period, the exercise log was used to collect the mediating variable about exercise compliance (time × frequency) data collection. this study compares the effectiveness of motivational interviews and self-efficacy theory-based exercise behavior intervention and home resistance exercise training programs. the result will show an empirical evidence for type 2 diabetic patients to increase physical activity and muscle strength in the future, and will also apply to training of muscle strengthening in diabetes and other chronic disease.

Eligibility criteria:
inclusion criteria: * diabetes type 2 * age \>50 years old * sedentary lifestyle (pase questionnaire leisure time physical activities score female \<30 points, male \<40 points) exclusion criteria: * severe congestive heart failure (new york heart association functional class iii and iv) * severe renal failure (estimated glomerular filtration rate \< 15 ml/min/1.73m2) * stroke ((the national institutes of health stroke scale \> 15) * peripheral arterial occlusive disease * foot ulcer over 6 month * severe muscle diseases and rheumatoid arthritis * cognitive or mental disorders who cannot understand and cooperate with the exercise plan * those who are accessed by the doctor to be avoided for exercise

Keywords: diabetes mellitus, type 2 resistance exercise muscle strength
piezoelectric drived microneedling in treating refractory skin diseases

Conditions: Skin Diseases; Hypertrophic Scar; Keloid; Plantar Wart; Warts; Skin Tumor

Summary: piezoelectric drived microneedling treats refractory skin disorders using hollow microneedles assisted by ultrasound. mechanically, the injection of medicine by hollow microneedling could makes the distribution of medicine more evenly. and the addition of ultrasound technique improves the effectiveness of microneedling. investigators plan to conduct a pilot study to investigate the efficacy of using piezoelectric drived microneedles in treating refractory skin diseases.

piezoelectric drived microneedling treats refractory skin disorders using hollow microneedles assisted by ultrasound. mechanically, the injection of medicine by hollow microneedling could makes the distribution of medicine more evenly. and the addition of ultrasound technique improves the effectiveness of microneedling. investigators plan to conduct a pilot study to investigate the efficacy of using piezoelectric drived microneedles in treating refractory skin diseases. investigators accept participants of hypertrophic scar, keloid and warts. for participants who are not candidates for traditional surgery, investigators will consider to accept carefully.

Eligibility criteria:
inclusion criteria: * age over 16 years * diagnosed by 2 or more professional dermatologists * willing to underwent a new treatment modality * follow up is easy to conduct exclusion criteria: * poor general condition * bleeding tendency * allergy to drug

Keywords: microneedling ultrasound refractory skin diseases piezoelectric drived
physiological changes of the mitral annulus after annuloplasty in barlow disease

Conditions: Barlow Disease (BD); Mitral Insufficiency

Summary: barlow disease (bd) is a common cause of mitral insufficiency. in 2012 the university hospital of basel started to perform a simplified mitral valve repair technique in bd just by implanting an annuloplasty-ring. it is hypothesized that the major mechanism of the valvular insufficiency in barlow disease is a deformation of the left ventricle and the posterior mitral annulus, causing its aberrant displacement during the systole towards posterior and basal and thus impairing the coaptation of the leaflets. this prospective individual mri study is to investigate the ventricle and the mitral annulus pre- and postoperatively for detailed analysis.


Eligibility criteria:
inclusion criteria: * identified barlow disease suffering from significant mitral insufficiency with indication to surgery exclusion criteria: * active endocarditis or any other etiology of mitral insufficiency else than barlow disease * inability to perform a cardiac mri (e.g., metallic implants, claustrophobia) * pregnancy * inability to give consent

Keywords: mitral annuloplasty mitral valve repair mitral annulus coaptation of mitral leaflets
safety and efficacy of early administration of dexamethasone in high-risk sepsis

Conditions: Sepsis

Summary: the purpose of this study is to investigate the safety and efficacy of early administration of two different doses of dexamethasone in high risk septic patients.

the septic adult patients of high risk would be enrolled in 2 emergency departments. sepsis would be defined by sepsis-3 definition. high risk is defined as initial systolic blood pressure less than 90 mmhg or blood lactate level over 2 mmol/l. the enrolled patients would be randomized to 3 groups: control, low dose dexamethasone (0.1 mg/kg iv), and high dose dexamethasone (0.2mg/kg iv). the study drug is blinded and administered after enrollment for 2 days. sample size would be 102, considering 10% of drop-out rate, allocating 30 patients to each groups. efficacy would be evaluated as follows; 28 day and 90 day mortality, time to septic shock, time to shock reversal, administration of steroid according to guideline, ventilator free days, continuous renal replacement, length of stay in icu or hospital, delta sofa score on day 3 and day 7, safety would be evaluated as follows; superinfection gastrointestinal bleeding, hyperglycemia, hypernatremia

Eligibility criteria:
inclusion criteria: * sepsis defined by sepsis-3 definition * initial systolic blood pressure \ 2mmol/l exclusion criteria: * advanced directive for "do not resuscitation" * recent systemic administration of glucocorticoid (4 weeks) * recent systemic administration of chemotherapy (4 weeks) * recent systemic administration of immunosuppressant (4 weeks) * expected life less than 90 days * transferred from other hospital * sepsis diagnosed 24 hours after ed admission * use of etomidate in ed * pregnant or on lactation * no informed consent

Keywords: sepsis, glucocorticoid